John Birkmeyer named executive VP for enterprise support systems at Dartmouth-Hitchcock health system.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOHN BIRKMEYER was named executive vice president for enterprise support services for the Dartmouth-Hitchcock health system.

Birkmeyer is the George D. Zuidema Professor of Surgery at the University of Michigan, and is head of the Center for Healthcare Outcomes and Policy. He also directs the Michigan Value Collaborative, a partnership between Blue Cross and Blue Shield of Michigan and leaders of 54 Michigan hospitals.

Between 1989, when he began his surgical residency, and 2004, when he was recruited to the University of Michigan, he served as chief of surgery at the White River Junction VA Medical Center, as chief of the section of general surgery at Dartmouth-Hitchcock, and as a core contributor to the Dartmouth Atlas of Healthcare. He was elected to the Institute of Medicine in 2006.

Birkmeyer’s research career has focused on understanding variation in surgical outcomes and cost-efficiency. He is also founder and chief scientific officer of ArborMetrix, a venture capital-funded analytics and services company.

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login